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Disordered Control of Intestinal Sweet Taste Receptor
Expression and Glucose Absorption in Type 2 Diabetes
Richard L. Young,1,2,3,4 Bridgette Chia,1,4 Nicole J. Isaacs,2 Jing Ma,2,5 Joan Khoo,2,6 Tongzhi Wu,2,3
Michael Horowitz,2,3 and Christopher K. Rayner2,3,4
We previously established that the intestinal sweet taste recep-
tors (STRs), T1R2 and T1R3, were expressed in distinct epithelial
cells in the human proximal intestine and that their transcript
levels varied with glycemic status in patients with type 2 diabetes.
Here we determined whether STR expression was 1) acutely
regulated by changes in luminal and systemic glucose levels, 2)
disordered in type 2 diabetes, and 3) linked to glucose absorp-
tion. Fourteen healthy subjects and 13 patients with type 2 di-
abetes were studied twice, at euglycemia (5.2 6 0.2 mmol/L) or
hyperglycemia (12.3 6 0.2 mmol/L). Endoscopic biopsy speci-
mens were collected from the duodenum at baseline and after
a 30-min intraduodenal glucose infusion of 30 g/150 mL water
plus 3 g 3-O-methylglucose (3-OMG). STR transcripts were quan-
tiﬁed by RT-PCR, and plasma was assayed for 3-OMG concentra-
tion. Intestinal STR transcript levels at baseline were unaffected
by acute variations in glycemia in healthy subjects and in type 2
diabetic patients. T1R2 transcript levels increased after luminal
glucose infusion in both groups during euglycemia (+5.8 3 104
and +5.8 3 104 copies, respectively) but decreased in healthy
subjects during hyperglycemia (21.4 3 104 copies). T1R2 levels
increased signiﬁcantly in type 2 diabetic patients under the same
conditions (+6.9 3 105 copies). Plasma 3-OMG concentrations
were signiﬁcantly higher in type 2 diabetic patients than in
healthy control subjects during acute hyperglycemia. Intestinal
T1R2 expression is reciprocally regulated by luminal glucose in
health according to glycemic status but is disordered in type 2
diabetes during acute hyperglycemia. This defect may enhance
glucose absorption in type 2 diabetic patients and exacerbate
postprandial hyperglycemia. Diabetes 62:3532–3541, 2013
Glucose in the small intestinal lumen inducesfeedback that regulates gastric emptying, ab-sorptive function, and energy intake (1–3),mediated both by vagal nerve pathways and
secretion of gut peptides (4), including glucose-dependent
insulinotropic polypeptide (GIP) from enteroendocrine
K cells and glucagon-like peptide 1 (GLP-1) from L cells.
These “incretins” substantially augment insulin secretion
when glucose is given orally compared with an isoglycemic
intravenous infusion (5). The rate of gastric emptying and
the secretion and action of the incretin hormones are both
key determinants of postprandial glycemia. However, the
precise mechanism of glucose detection in the small in-
testine remains unclear.
Lingual sweet taste cells possess two G-protein–coupled
receptors, T1R2 and T1R3, which form a heterodimeric
sweet taste receptor (STR) for sugars, D-amino acids,
sweet proteins, and artiﬁcial sweeteners (6,7). T1R2/R3
activation liberates the a-subunit of the G-protein gustdu-
cin (a-gustducin), leading to intracellular Ca2+ release,
gating of a taste-speciﬁc transient receptor potential ion
channel TRPM5 (8), cellular depolarization, and release of
mediators that activate lingual afferent nerves.
We, and others, have shown that STRs, a-gustducin, and
TRPM5 are also expressed with cellular and regional
speciﬁcity in the animal and human intestine, where they
may serve as glucose sensors (4,9–13). In addition to
expression in intestinal sweet taste cells, some of these
taste components are also expressed in separate intestinal
cell populations that detect umami (T1R3, a-gustducin,
TRPM5), bitter, and fats (a-gustducin, TRPM5) (4). STR
activation may be linked to gut hormone secretion, because
mice deﬁcient in T1R3 or a-gustducin exhibit defective
glucose-induced GLP-1 release (14), whereas the STR
blocker, lactisole, decreases GLP-1 secretion and increases
glycemic excursions after intragastric or intraduodenal
glucose infusion in humans (15,16). Animal studies also
indicate that STR activation increases the availability
and function of the primary intestinal glucose transporter,
sodium-glucose cotransporter-1 (SGLT-1) (17,18), although
this link has not been assessed directly in humans.
Patients with type 2 diabetes frequently demonstrate
disordered gastrointestinal responses to nutrients, with
delayed gastric emptying in up to 30–50%, abnormally
rapid emptying in a few (19,20), and a high prevalence of
gastrointestinal symptoms (21). GLP-1 and GIP secretion
has been inconsistently reported to be diminished in
patients with type 2 diabetes (22,23), whereas intestinal
levels of SGLT-1 and the capacity for glucose absorption
may be increased (24). Any of these abnormalities could
potentially relate to disordered intestinal sensing of glu-
cose. We previously reported that duodenal expression of
STRs during fasting was comparable in unselected patients
with type 2 diabetes and nondiabetic control subjects but
was inversely related to the blood glucose concentration at
the time of biopsy in type 2 diabetic patients (13). In
rodents, we, and others, have also shown that intestinal
STR transcript and protein levels are rapidly down-
regulated upon acute luminal exposure to glucose or arti-
ﬁcial sweeteners (13,25). Our current aims were, therefore,
to evaluate the modulation of duodenal STR expression in
response to acute changes in luminal and systemic glucose
exposure in healthy humans and to determine whether
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STR regulation is disordered in type 2 diabetes and related
to changes in glucose absorption and/or gut hormone se-
cretion.
RESEARCH DESIGN AND METHODS
Subjects. Fourteen healthy subjects and 13 patients with type 2 diabetes were
studied in randomized, crossover fashion. The mean duration of known di-
abetes in the latter group was 5 6 1 years, HbA1c was 6.3 6 0.2% (45 6 2
mmol/mol), and all were free of signiﬁcant comorbidities and managed by
diet alone. The protocol was approved by the Human Research Ethics Com-
mittee of the Royal Adelaide Hospital and conducted in accordance with the
Declaration of Helsinki as revised in 2000. Each subject provided written in-
formed consent.
Screening visit. Each subject attended the laboratory at 0830 h after an
overnight fast of 12 h for solids and 10 h for liquids. An intravenous cannula was
inserted for blood sampling, and subjects consumed a glucose drink (75 g
glucose dissolved in water to 300 mL, labeled with 150 mg 13C acetate) within
5 min (T =25 to 0 min). Blood was sampled at T =25, 30, 60, 120, and 180 min
to measure blood glucose by a glucometer (Medisense Precision QID; Abbott
Laboratories, Bedford, MA). Breath samples were collected before and every
5 min after oral glucose during the ﬁrst hour, and every 15 min for a further 2 h
to measure 13CO2 concentrations by isotope ratio mass spectrometer (ABCA
2020; Europa Scientiﬁc, Crewe, U.K.). The gastric half-emptying time was
calculated using the formula of Ghoos et al. (26). Gastrointestinal symptoms
were assessed by a standard questionnaire (maximum score, 27), as pre-
viously described (27). Autonomic nerve function was assessed in the type 2
diabetes patients using standardized cardiovascular reﬂex tests, with a score
$3 (of a maximum of 6) indicating autonomic dysfunction (28).
Endoscopy protocol.After the screening visit, each subject was studied twice,
separated by at least a week, with female subjects studied exclusively during
the follicular phrase of the menstrual cycle to limit variations in gut hormone
concentrations (29). Subjects attended the laboratory at 0830 h after an
overnight fast, and an insulin/glucose clamp was established to achieve
euglycemia (;5 mmol/L) or hyperglycemia (;12 mmol/L) (30). A 50-mL in-
travenous bolus of 25% glucose (Baxter Healthcare, Old Toongabbie, NSW,
Australia) was administered on the hyperglycemic day, and 0.9% saline
(Baxter Healthcare) on the euglycemic day, over 1 min each, followed by
continuous infusion of the same solution starting at 150 mL/h and adjusted
according to blood glucose measurements every 5 min on the hyperglycemic
day or remaining at 150 mL/h on the euglycemic day. On the euglycemic day,
25% dextrose was infused intravenously if the blood glucose concentration fell
below 5 mmol/L. In addition, 100 IU of insulin (Actrapid; Novo Nordisk,
Baulkham Hills, NSW, Australia), in 500 mL 4% succinylated gelatin solution
(Gelofusine; B. Braun Australia, Bella Vista, NSW, Australia), was infused in-
travenously at a variable rate to maintain euglycemia. Once blood glucose
concentrations were stable for 30 min (12.3 6 0.2 mmol/L on the hypergly-
cemic day or 5.2 6 0.2 mmol/L on the euglycemic day), a small diameter video
endoscope (GIF-XP160; Olympus, Tokyo, Japan) was passed via an anes-
thetized nostril into the second part of the duodenum, from which mucosal
biopsy specimens were collected using standard biopsy forceps and placed
into RNAlater (Qiagen, Sydney, NSW, Australia) or 4% paraformaldehyde for
2 h. At T = 0 an intraduodenal infusion containing 30 g glucose and 3 g
glucose absorption marker 3-O-methyglucose (3-OMG; Sigma-Aldrich, St. Louis,
MO) was commenced via the biopsy channel of the endoscope, and con-
tinued for 30 min (1 g/min; 4 kcal/min). At T = 10 and T = 30 min, additional
biopsy specimens were collected. Blood samples (20 mL) were taken every
10 min over 1 h to determine concentrations of 3-OMG, C-peptide, GLP-1,
and GIP.
Assays. Plasma total GLP-1 concentrations were measured by radioimmu-
noassay (GLPIT-36HK; Millipore, Billerica, MA) with sensitivity of 3 pmol/L and
intra- and interassay coefﬁcients of variation (CV) of 4.2% and 10.5%. Total
plasma GIP was measured by radioimmunoassay as previously reported, with
sensitivity of 2 pmol/L and intra- and interassay CV of 6.1% and 15.4%, re-
spectively (31). Plasma C-peptide concentrations were measured by ELISA
(10-1136-01; Mercodia, Uppsala, Sweden), with sensitivity of 15 pmol/L and
intra- and interassay CV of 3.6% and 3.3%. Serum 3-OMG concentrations were
measured by liquid chromatography and mass spectrometry, with sensitivity
of 10 pmol/L (32).
Quantiﬁcation of gene expression by real-time RT-PCR. RNA was
extracted from tissues using an RNeasy Mini kit (Qiagen), following the
manufacturer’s instructions, and RNA yield and quality were determined using
a NanoDrop (NanoDrop Technologies, Wilmington, DE). Quantitative real-
time RT-PCR was then used to determine the absolute expression of sweet
taste molecules. Validated human primers for T1R2, a-gustducin, and TRPM5
were used as primer assays (QuantiTect, Qiagen). T1R3 primers were
designed using Primer 3.0 software (Applied Biosystems, Foster City, CA)
based on target sequences obtained from the National Center for Bio-
technology Information nucleotide database (Table 1). Absolute standard
curves were generated by including known copy number standards in RT-PCR
for each target (Table 2), as described (13). RT-PCR was performed on
a Chromo4 (MJ Research, Waltham, MA) real-time instrument attached to
a PTC-200 Peltierthermal cycler (MJ Research) using a QuantiTect SYBR
Green one-step RT-PCR kit (Qiagen) according to the manufacturer’s speci-
ﬁcations, as previously described (13). Each assay was performed in triplicate
and included internal no-template and no-RT controls. All replicates were
averaged for ﬁnal mRNA copy number, which was expressed as copies/50 ng
of total RNA.
Immunohistochemistry. Fixed tissues were cryoprotected (30% sucrose in
PBS), embedded in cryomolds, and frozen before sectioning at 6–10 mm
(Cryocut 1800; Leica Biosystems, Nussloch, Germany) and thaw mounting
onto gelatin-coated slides. Immunoreactivity was detected using rabbit T1R2
primary (H90, 1:400, SC-50305; Santa Cruz Biotechnology, Santa Cruz, CA),
goat GLP-1 primary (1:400, SC-7782; Santa Cruz Biotechnology), monoclonal
5-hydroxytryptamine (5-HT; 1:1000, M0758; Dako Australia, Victoria, Australia),
and GIP primary antibodies (1:800, AB30679; Abcam). All were visualized
using species-speciﬁc secondary antibodies conjugated to Alexa Fluor dyes
(1:200 in PBS-Tween 20) as previously described (12,13). Antigen retrieval
(S1700; Dako) was performed for T1R2 according to the manufacturer’s
instructions. Nucleated epithelial cells immunopositive for individual targets
were counted per square millimeter of high-power ﬁeld and averaged over at
least 10 intact transverse sections per subject.
Data analysis. The incremental area under the curve (iAUC) for 3-OMG, GLP-1,
and GIP concentrations was calculated using the trapezoidal rule (33) and
analyzed by one-factor ANOVA using Prism software (version 6.0; GraphPad
Software Inc., La Jolla, CA). These variables were also assessed using
repeated-measures ANOVA, with treatment and time as factors. Post hoc
comparisons, adjusted for multiple comparisons by Holm-Sidak’s correc-
tion, were performed if ANOVAs showed signiﬁcant effects. One-way
ANOVA, with Holm-Sidak’s post hoc test, was used to compare differences
in duodenal levels of STR transcripts between healthy subjects and type 2
diabetic patients. Relationships between transcript expression and other
factors were evaluated by the Pearson correlation coefﬁcient (r). We cal-
culated that 12 subjects had 80% power to detect a one-third difference in
duodenal T1R2 expression in paired studies (a = 0.05), compared with control
(13). P values # 0.05 were considered statistically signiﬁcant. Data are ex-
pressed as mean 6 SEM.
RESULTS
All subjects tolerated the study well. The patients with
type 2 diabetes were older than the healthy subjects, but
TABLE 1
Human primers used for absolute quantiﬁcation of target genes in RT-PCR
Gene Accession no. Primer information
Amplicon
length (bp)
T1R2 (TASR2) NM_152232 QT01026508 94
T1R3 (TASR3) NM_152228 Forward (59 to 39): CAAAACCCAGACGACATCG 101
Reverse (59 to 39): CATGCCAGGAACCGAGAC
Gagust (GNAT3) XM_001129050 QT00049784 111
TRPM5 NM_014555 QT00034734 115
QT, QuantiTect primer assay (Qiagen).
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gastrointestinal symptom scores, BMI, and gastric empty-
ing of glucose did not differ (Table 3). Five type 2 diabetic
patients had autonomic dysfunction, but none had evi-
dence of peripheral neuropathy, nephropathy, retinopathy,
or macrovascular complications. As expected, blood glu-
cose concentrations were higher in type 2 diabetic patients
during fasting and after oral glucose (P , 0.05; Fig. 1A).
Baseline STR expression. Transcripts for T1R2, T1R3,
a-gustducin, and TRPM5 were readily detected in duode-
nal biopsy specimens by quantitative RT-PCR. TRPM5 was
the most abundant STR transcript in all subjects, with
lower levels of a-gustducin and much lower levels of T1R2
and T1R3; T1R2 was the least expressed transcript (Fig. 2A).
TRPM5 transcript levels in healthy subjects during eugly-
cemia were 34 6 8-fold higher than those of T1R2 (P ,
0.001), whereas a-gustducin levels were 22 6 7-fold higher
(P , 0.05) and T1R3 levels were 12 6 5-fold higher.
Effects of acute changes in glycemia on STR expression.
Fasting expression of STR transcripts was unaffected by
the glycemic state in health or type 2 diabetes and did not
differ between the groups (Fig. 2B–E).
Effects of luminal glucose on duodenal STR expression.
Owing to intersubject variability in STR expression, re-
sponses to luminal glucose were evaluated as changes
from baseline. During euglycemia, T1R2 transcript levels
increased in response to duodenal glucose infusion in
health and in type 2 diabetes after 30 min (+5.9 3 104
and +5.8 3 104 copies; Fig. 3A). During hyperglycemia,
T1R2 transcript levels decreased in healthy subjects after
30 min (21.4 3 104 copies) but increased in type 2 di-
abetic patients (+6.9 3 105 copies), so that levels in
health were lower at 30 min during hyperglycemia than
euglycemia and lower than in type 2 diabetic patients
during either glycemic state (subject 3 time interactions
P , 0.01 for each). Levels of T1R3, a-gustducin, and
TRPM5 transcript, in contrast, did not signiﬁcantly change
in response to luminal glucose under either glycemic con-
dition (Fig. 3B–D).
Plasma hormone concentrations. Fasting plasma GLP-1
concentrations did not differ between health and type 2
diabetes and were not acutely affected by the glycemic
state. Plasma GLP-1 increased in response to duodenal
glucose infusion in all groups (P , 0.001; Fig. 1C), with
higher concentrations evident in type 2 diabetic patients at
40 min irrespective of glycemic status (subject 3 time
interactions P , 0.01) and at 50 min during euglycemia
compared with healthy subjects (subject 3 time inter-
actions P, 0.05). The iAUC for GLP-1 was higher in type 2
diabetic patients during euglycemia and hyperglycemia
compared with healthy subjects (P , 0.05 each; Table 4).
Fasting plasma GIP concentrations did not differ be-
tween healthy subjects and type 2 diabetic patients and
were not acutely affected by the glycemic state. Plasma
GIP increased in response to duodenal glucose infusion in
both groups (P , 0.001; Fig. 1D), with higher GIP con-
centrations evident in type 2 diabetic patients at 40 min
irrespective of glycemic status and higher concentrations
during euglycemia at 20 and 50 min compared with healthy
subjects (subject 3 time interaction P , 0.05). The iAUC
was higher in type 2 diabetic patients during euglycemia
compared with healthy subjects (P , 0.05; Table 4).
Fasting C-peptide concentrations were higher during
hyperglycemia than during euglycemia in healthy subjects
(P , 0.001; Fig. 1E) but not in type 2 diabetic patients.
C-peptide concentrations increased in response to duo-
denal glucose infusion in both groups during hyperglyce-
mia (subject 3 time interaction P , 0.05; iAUC P , 0.001)
but not during euglycemia (Fig. 1E and Table 4). C-peptide
concentrations during hyperglycemia were higher in healthy
subjects than in type 2 diabetic patients throughout the
TABLE 2
Human primers used to generate RT-PCR product containing target amplicon to create absolute standard curves
Gene Forward primer (59–39) Reverse primer (59–39)
Amplicon
length (bp)
T1R2 TACCTGCCTGGGGATTAC AAATAGGGAGAGGAAGTTGG 390
T1R3 AGGGCTAAATCACCACCAGA CCAGGTACCAGGTGCACAGT 953
Gagust GAGGACCAACGACAACTTTA ACAATGGAGGTTGTTGAAAA 491
TRPM5 CTTGCTGCCCTAGTGAAC CTGCAGGAAGTCCTTGAGTA 639
TABLE 3
Demographic, anthropometric, metabolic, and gastrointestinal parameters of the study participants
Healthy subjects Type 2 diabetic patients P value




Age (years) 31 6 3 66 6 2 ,0.001
BMI (kg/m2) 25 6 1 27 6 1 NS
HbA1c (%) 6.3 6 0.2
Duration of known diabetes (years) 5.0 6 0.9
Fasting blood glucose at screening (mmol/L) 5.9 6 0.2 7.4 6 0.4 ,0.01
2-h blood glucose after oral load (mmol/L) 6.3 6 0.4 12.3 6 1.1 ,0.001
Gastrointestinal symptom score (maximum, 27) 1.9 6 0.6 1.2 6 0.3 NS
Autonomic function score (maximum, 6) 2.6 6 0.5
Gastric half-emptying (min) 123 6 8 130 6 12 NS
Data are number or mean 6 SEM. NS, not signiﬁcant.
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FIG. 1. Effects of oral glucose or intraduodenal (ID) glucose infusion on blood glucose levels and plasma levels of hormones and the glucose
absorption marker 3-OMG in healthy control (HC) subjects and type 2 diabetic (T2D) patients during euglycemia or hyperglycemia. (A) Blood
glucose levels after a glucose drink in HC subjects and T2D patients. *P < 0.05, #P < 0.01, dP < 0.001 T2D compared with HC. (B) Blood glucose
levels after ID glucose infusion during glycemic clamp. dP < 0.001 HC euglycemic compared with hyperglycemic groups and T2D euglycemic
compared with T2D hyperglycemic; *P < 0.05 T2D euglycemic compared with HC euglycemic; #P < 0.05 T2D hyperglycemic compared with HC
hyperglycemic. (C) Plasma GLP-1. *P < 0.05 T2D groups compared with HC euglycemic; #P < 0.01 T2D groups compared with HC hyperglycemic.
(D) Plasma GIP. *P < 0.05 T2D groups compared with HC euglycemic; **P < 0.05 T2D groups compared with HC hyperglycemic; ***P < 0.05 T2D
euglycemic compared with HC groups. (E) C-peptide. dP < 0.001 HC hyperglycemic compared with euglycemic groups; *P < 0.05 T2D hypergly-
cemic compared with other groups. (F) 3-OMG. dP < 0.001 T2D hyperglycemic compared with other groups. Data are mean 6 SEM; signiﬁcance
represents treatment 3 time interactions.
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glucose infusion (subject 3 time interaction P , 0.05; iAUC
P , 0.001).
Serum 3-OMG concentrations. Serum 3-OMG concen-
trations increased over time in all groups but were higher
at 60 min in type 2 diabetic patients during hyperglycemia
than in any other group (subject 3 time interaction P ,
0.001; Fig. 1F). The iAUC for 3-OMG was higher in type 2
diabetic patients and in healthy subjects during hypergly-
cemia than during euglycemia (P , 0.05; Table 4).
Phenotype of human intestinal sweet taste cells.
Immunolabeling for T1R2 was evident in single cells dis-
persed throughout the mucosal epithelium in healthy
subjects and type 2 diabetic patients (Fig. 4). Immuno-
positive cells showed a homogenous distribution of the
label throughout the cytoplasm, were largely open or
“ﬂask-shaped,” and were found with equal frequency
within villi or crypts. In dual-labeling experiments in
healthy subjects, 19 6 11% of T1R2-labeled duodenal cells
FIG. 2. Absolute transcript levels of STR in the duodenum of healthy subjects and type 2 diabetic patients at stable euglycemia and hyperglycemia.
Absolute expression (copy number) of STR transcripts at baseline in the duodenum of healthy subjects (A) or patients with type 2 diabetes (B).
(A) TRPM5 levels were 15-fold higher, a-gustducin 9-fold higher, and T1R3 3-fold higher than T1R2 levels in healthy subjects. (B) TRPM5 levels
were 29-fold higher, a-gustducin 11-fold higher, and T1R3 5-fold higher than T1R2 levels in patients with type 2 diabetes. *P < 0.05 and #P < 0.01
compared with T1R2. Duodenal levels of T1R2 (C), T1R3 (D), a-gustducin (E), and TRPM5 (F) transcript in healthy control (HC) subjects and
type 2 diabetic (T2D) patients at stable euglycemia or hyperglycemia. No signiﬁcant differences in transcript levels were detected at stable
baseline. Data are mean 6 SEM. a-GD, a-gustducin
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coexpressed GLP-1, whereas 13 6 8% of L cells coex-
pressed T1R2 (Fig. 4A). In a similar manner, 15 6 10% of
T1R2-labeled duodenal cells coexpressed GIP, whereas 126
8% of K cells coexpressed T1R2 (Fig. 4B). Separate pop-
ulations of T1R2-labeled cells coexpressed 5-HT (31 6 6%),
whereas 5 6 1% of enterochromafﬁn (EC) cells coex-
pressed T1R2 in healthy subjects (Fig. 4C). During fast-
ing, an equivalent number of T1R2 immunopositive cells
were evident in healthy subjects and in type 2 diabetic
patients, under euglycemia or hyperglycemia, and the
FIG. 3. Effects of intraduodenal glucose infusion on sweet taste molecule transcript levels in healthy control (HC) subjects and type 2 diabetic
(T2D) patients during euglycemia or hyperglycemia. (A) Change in absolute expression of T1R2 in human duodenum during intraduodenal glucose
infusion under euglycemic or hyperglycemic clamp. #P < 0.01 HC hyperglycemic compared with all other groups. T1R3 (B), a-gustducin (C), and
TRPM5 (D). Data are mean 6 SEM.
TABLE 4
iAUC for GLP-1, GIP, C-peptide, and 3-OMG in healthy subjects and type 2 diabetic patients
Healthy subjects Type 2 diabetic patients P value
iAUC60 (pmol/L/min) Euglycemia Hyperglycemia Euglycemia Hyperglycemia (one-factor ANOVA)
GLP-1 1,530 6 152 1,403 6 122 2,373 6 219a,b 2,446 6 354a,b ,0.05a,b
GIP 1,308 6 126 1,261 6 160 1,978 6 181a,b 1,849 6 197 ,0.05a,b
C-peptide 2,028 6 178 7,796 6 715a 1,599 6 184b 4,756 6 405a,b,c ,0.001a,b,c
3-OMG 542 6 45 747 6 55a 565 6 48b 715 6 37a,c ,0.05a,b,c
iAUC60, incremental area under the curve at 60 min. Data are mean 6 SEM. Signiﬁcantly different from
ahealthy euglycemia, bhealthy
hyperglycemia, and ctype 2 diabetes euglycemia.
R.L. YOUNG AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 62, OCTOBER 2013 3537
number did not change during the duodenal glucose in-
fusion. Similarly, the proportion of cells immunopositive
for GLP-1, GIP, and 5-HT did not differ between healthy
subjects and type 2 diabetic patients or with glycemic
state or exposure to luminal glucose, although a trend for
increased L cells in fasting type 2 diabetic patients was
evident (data not shown; P = 0.07).
Relationships between variables. Absolute copy num-
bers of STR transcripts during fasting and after the 30-min
glucose infusion did not correlate with age, sex, BMI,
symptom score, or gastric half-emptying time in either
group, and in type 2 diabetic patients, they were not re-
lated to duration of diabetes, HbA1c, autonomic dysfunc-
tion, or symptom score. In contrast, the change in T1R2
transcript level after luminal glucose exposure correlated
with the iAUC for 3-OMG in healthy subjects during
euglycemia (r = 0.73, P , 0.05), and the change in TRPM5
transcript level with plasma GLP-1 concentrations at
30 min (r = 0.62, P , 0.05) in the same group. Changes in
T1R2 (r = 0.78, P , 0.01) and T1R3 transcript levels (r =
0.59, P , 0.05) in type 2 diabetic patients during hyper-
glycemia also correlated with plasma GIP concentrations
at 30 min, and the change in T1R2 correlated with the
iAUC for GIP (r = 0.69, P , 0.05).
DISCUSSION
This study is the ﬁrst to deﬁne changes in expression of
intestinal STR transcripts in healthy humans and patients
with type 2 diabetes in response to acute changes in sys-
temic and luminal glucose. We have shown that absolute
levels of STR transcripts are unaffected by acute variations
in glycemia during fasting in either group but that T1R2
expression increases upon exposure to luminal glucose
during euglycemia. In contrast, T1R2 expression decreases
markedly in response to luminal glucose during hypergly-
cemia in health but increases under the same conditions in
type 2 diabetes. Type 2 diabetic patients also exhibit in-
creased glucose absorption during acute hyperglycemia
compared with healthy subjects, suggesting that dysregu-
lated expression of intestinal STRs can perpetuate post-
prandial hyperglycemia in this group.
We conﬁrmed our previous observation that fasting STR
transcript levels are similar in health and in type 2 diabetes
irrespective of age, sex, or BMI (13). Although we pre-
viously observed that levels of STR transcript were in-
versely related to fasting blood glucose concentrations in
unselected type 2 diabetic patients presenting for endo-
scopy, we have now established unequivocally that acute
changes in glycemia do not inﬂuence fasting intestinal STR
expression in health or in “well-controlled” type 2 diabetes.
The apparent discrepancy in these observations may re-
ﬂect the effects of more longstanding hyperglycemia or
differences in the duration of fasting in the earlier cross-
sectional study. We have now shown that the intestinal
STR system is, in contrast, highly responsive to the pres-
ence of luminal glucose, with rapid and reciprocal regu-
lation of T1R2 transcripts in health, depending on the
prevailing blood glucose concentration. Comparable changes
were evident in T1R3 and TRPM5 transcript levels, al-
though these were not statistically signiﬁcant. Increased
intersubject variability seen for T1R3 and TRPM5 tran-
script levels may be due to their expression in additional
populations of intestinal cells tuned to detect other taste
modalities and, therefore, unresponsive to luminal and/or
systemic glucose.
Healthy subjects who displayed the largest glucose-
induced increase in duodenal T1R2 transcript levels dur-
ing euglycemia had the highest plasma concentrations of
the glucose absorption marker 3-OMG. Because SGLT-1 is
responsible for the active transport of luminal 3-OMG, our
ﬁndings support a role of intestinal T1R2 signals in the
regulation of glucose absorption via SGLT-1. Indeed, in-
testinal STR activation has been shown to upregulate
SGLT-1 transcript, apical protein, and function in a number
of species (17,18). Accordingly, reciprocal regulation of
T1R2 in human health may increase SGLT-1 function at
euglycemia to facilitate glucose absorption and reduce
FIG. 4. Subsets of L cells, K cells, and EC cells express STR in healthy human duodenum. (A) Immunolabeling for GLP-1 was present in 196 11% of
T1R2-labeled duodenal cells in healthy control subjects at euglycemia, whereas 13 6 8% of L cells coexpressed T1R2. (B) GIP was present in 15 6
10% of T1R2-labeled cells in healthy control subjects at euglycemia, whereas 12 6 8% of K cells coexpressed T1R2. (C) In a similar manner,
separate populations of T1R2-labeled cells coexpressed 5-HT (31 6 6%), whereas 5 6 1% of EC cells coexpressed T1R2. (A–C) Scale bar = 20 mm.
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SGLT-1 function during hyperglycemia to limit post-
prandial glycemic excursion. However, despite a reduction
in T1R2 transcript after luminal glucose exposure during
hyperglycemia, our healthy subjects still displayed greater
rates of glucose absorption than during euglycemia, which
might be accounted for by changes in SGLT-1 lagging be-
hind those in T1R2. Our ﬁnding that plasma 3-OMG con-
centrations were elevated in type 2 diabetic patients
during hyperglycemia is in keeping with the concept that
SGLT-1 transporter capacity was maintained, or increased,
in the presence of luminal glucose under these conditions.
In fact, even small changes in SGLT-1 may increase this
risk, because type 2 diabetic patients are reported to have
up to fourfold higher levels of transcript, protein, and
function of this transporter at baseline compared with
healthy control subjects (24). We note that an increased
level of facilitated glucose transport via the basolateral
glucose transporter GLUT2 may have contributed to
plasma levels of 3-OMG in the current study; however, the
role of STR signals to direct the apical insertion of GLUT2
in enterocytes appears to be limited to rodents (25,34).
The link between STR stimulation and incretin hormone
release in healthy humans is not clear. Most in vivo studies
indicate that acute administration of nonnutritive sweet-
eners does not trigger incretin secretion in humans or
rodents (35–37). Nonetheless, we observed that subsets
of duodenal L cells, K cells, and EC cells were immu-
nopositive for T1R2, in accord with previous reports
(4,12,14). Together with positive associations between lu-
minal glucose-induced changes in some STR transcripts
and measures of GLP-1 and GIP secretion in the current
study, it remains possible that STRs do have a regulatory
role in gut hormone release. The inhibition of glucose-
induced GLP-1 secretion in healthy humans by the STR
blocker, lactisole (15), supports this concept. We also
recognize that STR signals may serve autocrine and/or
paracrine functions within the intestinal mucosa that are
not reﬂected in circulating gut hormone concentrations;
the latter appear to be a blunt marker for local concen-
trations of GLP-1 (38). There is also a large body of evi-
dence indicating that the intestinotrophic gut peptide,
glucagon-like peptide 2 (GLP-2), coreleased from L cells
with GLP-1, is a powerful local stimulus to increase in-
testinal glucose transport via SGLT-1 and GLUT2 in
rodents and in patients with short bowel syndrome (39–
41). Importantly, GLP-2 release has recently been revealed
as STR-dependent in animals and in a human enter-
oendocrine cell line (42,43), highlighting an important link
between STRs and GLP-2 in the regulation of intestinal
glucose transport.
Reports concerning postprandial incretin hormone re-
lease in patients with type 2 diabetes have been in-
consistent, with plasma GLP-1 concentrations after
a mixed meal being either reduced (22) or intact (44), al-
though such studies are potentially confounded by failure
to control for differences in the rate of gastric emptying,
which is frequently delayed in longstanding diabetes or
during acute hyperglycemia (20). Our observation that
GLP-1 and GIP responses to a standardized rate of duo-
denal glucose infusion were maintained, and indeed in-
creased, in type 2 diabetic patients, supports our previous
ﬁndings (45) and is in keeping with the trend for increased
L-cell density in these patients in the current study and
a report of an increased density of L cells and mixed L/K
cells in the duodenum of well-controlled type 2 diabetic
patients (46). There is now strong evidence that SGLT-1
transport is a key stimulus for release of GLP-1 and GIP,
which occurs even after exposure to nonmetabolized
SGLT-1 substrates and is inhibited by pharmacological
blockade or genetic ablation of SGLT-1 in rodents (47–49).
Therefore, increased SGLT-1 capacity could explain en-
hanced glucose-induced GLP-1 and GIP responses in our
type 2 diabetic patients. Any deﬁciency in the incretin ef-
fect in type 2 diabetes is likely to be explained by im-
paired b-cell function rather than by deﬁcient incretin
hormone secretion (45,50), and indeed, defective C-peptide
responses in our type 2 diabetic patients during hypergly-
cemia support this assertion. Acute hyperglycemia had no
effect on GLP-1 or GIP secretion, as noted previously
(51,52). Although SGLT-1 transport appears a major de-
terminant of GLP-1 and GIP release, other transporters
(49,53) or signaling pathways (54) may also be involved, so
increased glucose absorptive capacity during hyperglyce-
mia may not necessarily result in enhanced GLP-1 or GIP
concentrations.
Our study had a number of limitations. Transcriptional
regulation of intestinal T1R2 occurred rapidly in humans,
but we did not quantify changes in STR protein in parallel
due to ethical considerations on the additional biopsy
specimens required. However, similarly rapid changes in
these proteins after glucose or sucralose exposure are
known to occur in apical membrane vesicles of rat jeju-
num (25). We did not assess effects on SGLT-1 transcript
or protein here, although measures of glucose absorption
with 3-OMG reﬂect, in large part, SGLT-1 function as the
primary intestinal glucose transporter in humans. There
was considerable interindividual variability in baseline
expression of intestinal STR transcripts, so that our study
was insufﬁciently powered to detect relationships between
absolute transcript levels and concentrations of gut hor-
mones and 3-OMG. Our 3-OMG measurements were lim-
ited to 60 min, and differences between groups or glycemic
states might have become more marked after this point.
The duodenal glucose infusion was also relatively brief,
being limited by the tolerability of unsedated endoscopy.
Our type 2 diabetic patients had relatively good glycemic
control, and more marked differences from health might
be observed in patients with a higher HbA1c. The type 2
diabetic patients were older than the healthy control sub-
jects, although we have not previously shown any age-
related differences in postprandial GLP-1 responses (55).
In conclusion, we have shown that the intestinal STR
system is reciprocally regulated in the presence of luminal
glucose according to glycemic status in health but not in
type 2 diabetes. In the latter, T1R2 dysregulation poten-
tially increases the risk of postprandial hyperglycemia, but
the intestinal STR system appears unlikely to be a major
determinant of circulating GLP-1 or GIP concentrations in
humans.
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